StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Total Tests Processed by Quarter

Total Tests Processed — Lab + Constellation Platform (tests)

Natera Total Tests Processed: 1,043,900.00 tests in Q2 2026, up 22.4% from a year earlier. That is the highest of the 35 quarters on record here.

Latest, Q2 2026
1,043,900.00
Period ended Jun 30, 2026
Change on a year earlier
+22.4%
853,100.00 in Q2 2025
History
35 quarters
Since Q1 2017
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“Natera processed approximately 1,043,900 tests in the second quarter of 2026, including approximately 1,030,100 tests accessioned in its laboratory, compared to approximately 853,100 tests processed, including approximately 839,300 tests accessioned in its laboratory, in the second quarter of 2025”

Source: Form 8-K Ex 99.1 (2026-08-06) ↗

Primary operational volume KPI: total molecular diagnostic tests processed across Women's Health (Panorama NIPT, Horizon Carrier Screening, Empower, Vistara, Spectrum), Oncology (Signatera MRD, Altera), and Organ Health (Prospera, Renasight).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Tests Processed — Lab + Constellation Platform (tests)Year on yearSource
Q2 2026Jun 30, 20261,043,900.00+22.4%Form 8-K Ex 99.1 (2026-08-06) ↗
Q1 2026Mar 31, 20261,013,600.00+18.5%Form 10-Q (2026-03-31) ↗
Q4 2025Dec 31, 2025923,600.00+16.5%Form 8-K Ex 99.1 (2026-02-26) ↗
Q3 2025Sep 30, 2025893,600.00+15.2%Form 8-K Ex 99.1 (2025-11-06) ↗
Q2 2025Jun 30, 2025853,100.00+12.2%Form 8-K Ex 99.1 (2026-08-06) ↗
Q1 2025Mar 31, 2025855,100.00+16.2%Form 10-Q (2026-03-31) ↗
Q4 2024Dec 31, 2024792,800.00+26.5%Form 8-K Ex 99.1 (2026-02-26) ↗
Q3 2024Sep 30, 2024775,800.00+23.9%Form 8-K Ex 99.1 (2025-11-06) ↗
Q2 2024Jun 30, 2024760,300.00+23.2%Form 8-K Ex 99.1 (2025-08-07) ↗
Q1 2024Mar 31, 2024735,800.00+17.5%Form 10-Q (2025-03-31) ↗
Q4 2023Dec 31, 2023626,800.00+12.0%Form 8-K Ex 99.1 (2025-02-27) ↗
Q3 2023Sep 30, 2023626,000.00–Form 8-K Ex 99.1 (2024-11-12) ↗
Q2 2023Jun 30, 2023617,200.00+23.5%Form 8-K Ex 99.1 (2024-08-08) ↗
Q1 2023Mar 31, 2023626,200.00+28.0%Form 10-Q (2024-03-31) ↗
Q4 2022Dec 31, 2022559,700.00+27.6%Form 8-K Ex 99.1 (2024-02-28) ↗
Q2 2022Jun 30, 2022499,900.00+33.1%Form 8-K Ex 99.1 (2022-08-04) ↗

Breakdown

What makes up total Tests Processed

Cite this data

StockData. (2026). Natera Total Tests Processed, quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-tests-processed-total

See every metric in the Natera KPI table. Data updated Nov 2, 2026.